PharmTech Drug Digest 11.20
|Articles|December 29, 2008

Prescription Information Needs to be More Useful

A newly released study from the US Food and Drug Administration demonstrates that the printed information retail pharmacies provide to patients regarding medication use and risk of their prescriptions is not easy to read or understand.

Rockville, MD (Dec. 29)-A newly released study from the US Food and Drug Administration demonstrates that the printed information retail pharmacies provide to patients regarding medication use and risk of their prescriptions is not easy to read or understand. Even though 94% of consumers receive consumer medication information (CMI), only 75% of that information met the minimum “usefulness” requirement, said the authors of the Expert and Consumer Evaluation of Consumer Medication Information study.

In 1996, Congress requested that 95% of all new prescriptions be accompanied by useful CMI by 2006. The study does reveal some improvements since a similar study was conducted in 2001. The earlier report found that 89% of patients received CMI but only 50% of that information met the minimum usefulness criteria.

“The current voluntary system has failed to provide consumers with the quality information they need in order to use medicines effectively and safely,” said Janet Woodcock, MD, director of FDA’s Center for Drug Evaluation and Research, in a Dec. 16 FDA press release.

CMI is supposed to include the drug’s name and uses, how to monitor for improvement in the condition being treated, contraindications, symptoms of adverse reactions and what to do, and certain general information.

To improve the situation, the FDA Risk Communication Advisory Committee is holding a public meeting in early 2009 to discuss the study’s findings. An agency website is also available for public comment and feedback.

Read the full study here.


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.